danegaptide + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Focus of Study is STEMI
Conditions
Focus of Study is STEMI
Trial Timeline
Nov 1, 2013 → Jun 8, 2016
NCT ID
NCT01977755About danegaptide + Placebo
danegaptide + Placebo is a phase 2 stage product being developed by Zealand Pharma for Focus of Study is STEMI. The current trial status is completed. This product is registered under clinical trial identifier NCT01977755. Target conditions include Focus of Study is STEMI.
What happened to similar drugs?
0 of 1 similar drugs in Focus of Study is STEMI were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01977755 | Phase 2 | Completed |
Competing Products
5 competing products in Focus of Study is STEMI
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 2 | 27 |
| Nascobal nasal spray (cyanocobalamin, USP) + Vitamin B12-ratiopharm N, injection solution | Swedish Orphan Biovitrum | Phase 1 | 29 |
| LYBALVI | Alkermes | Phase 1 | 26 |
| S303 Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells (RBCs) | Cerus | Phase 2 | 25 |
| S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - Control | Cerus | Phase 3 | 30 |